Advertisement

Drugs & Aging

, Volume 36, Issue 2, pp 125–136 | Cite as

Approaches to Deprescribing Psychotropic Medications for Changed Behaviours in Long-Term Care Residents Living with Dementia

  • Stephanie L. HarrisonEmail author
  • Monica Cations
  • Tiffany Jessop
  • Sarah N. Hilmer
  • Mouna Sawan
  • Henry Brodaty
Review Article

Abstract

Psychotropic medications have a high risk of serious adverse events and small effect size for changed behaviours for people with dementia. Non-pharmacological approaches are recommended as first-line treatment for changed behaviours, yet psychotropic medications remain highly prevalent in long-term aged care settings. This narrative review describes the current evidence regarding deprescribing psychotropic medications for people with dementia in long-term care. Deprescribing psychotropic medications can be achieved without harm to the person with dementia, and most people experience no withdrawal symptoms. Interventions to deprescribe psychotropic medications should be multifactorial, including lowering the dose of the medication over time, educational interventions and psychological support. However, implementing this is a significant challenge due to the overreliance on psychotropic medications for behavioural management in long-term aged care. Facilitators to deprescribing psychotropic medications in long-term care include multidisciplinary teams with adequate training, education and managerial support, engaging residents and families and change ‘champions’. Deprescribing practices should be person-centred, and an individualised deprescribing protocol should be in place, followed by careful monitoring of the individual. The person with dementia and their family, general practitioner, pharmacist, and allied health and direct care staff should all be involved throughout the deprescribing process. Direct care staff need adequate support, education and training, so they can effectively help the individual and implement person-centred approaches in the absence of psychotropic medications. Effective communication between residents and staff and amongst staff is consistently shown to be an important factor for deciding whether deprescribing of a medication should occur and the successful implementation of deprescribing psychotropic medications.

Notes

Compliance with Ethical Standards

Conflict of interest

Henry Brodaty is an Advisory Board Member for Nutricia. Monica Cations has been employed in the past 5 years to assist with data collection for Alzheimer’s disease drug trials funded by Janssen and Merck. Stephanie Harrison, Tiffany Jessop, Sarah Hilmer and Mouna Sawan report no conflicts of interest.

Funding

No specific funding sources were received for the preparation of this manuscript.

References

  1. 1.
    NHS England. Optimising treatment and care for people with behavioural and psychological symptoms of dementia. 2017. http://medicine.exeter.ac.uk/media/universityofexeter/medicalschool/pdfs/nhs-dementia-best-practice-guide.pdf. Accessed 4 Apr 2018.
  2. 2.
    Laver K, Cumming RG, Dyer SM, Agar MR, Anstey KJ, Beattie E, et al. Clinical practice guidelines for dementia in Australia. Med J Aust. 2016;204(5):191–3.Google Scholar
  3. 3.
    National Collaborating Centre for Mental Health. Dementia: a NICE-SCIE guideline on supporting people with dementia and their carers in health and social care. Leicester: British Psychological Society; 2007.Google Scholar
  4. 4.
    Bjerre LM, Farrell B, Hogel M, Graham L, Lemay G, McCarthy L, et al. Deprescribing antipsychotics for behavioural and psychological symptoms of dementia and insomnia: evidence-based clinical practice guideline. Can Fam Physician. 2018;64(1):17–27.Google Scholar
  5. 5.
    Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, et al. The American Psychiatric Association practice guideline on the use of antipsychotics to treat agitation or psychosis in patients with dementia. Am J Psychiatry. 2016;173(5):543–6.Google Scholar
  6. 6.
    Dyer SM, Harrison SL, Laver K, Whitehead C, Crotty M. An overview of systematic reviews of pharmacological and non-pharmacological interventions for the treatment of behavioral and psychological symptoms of dementia. Int Psychogeriatr. 2018;30(3):295–309.Google Scholar
  7. 7.
    Westbury J, Gee P, Ling T, Kitsos A, Peterson G. More action needed: psychotropic prescribing in Australian residential aged care. Aust N Z J Psychiatry. 2018.  https://doi.org/10.1177/0004867418758919.Google Scholar
  8. 8.
    Van Leeuwen E, Petrovic M, van Driel ML, De Sutter AI, Vander Stichele R, Declercq T, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018;3:Cd007726.Google Scholar
  9. 9.
    Lemay CA, Mazor KM, Field TS, Donovan J, Kanaan A, Briesacher BA, et al. Knowledge of and perceived need for evidence-based education about antipsychotic medications among nursing home leadership and staff. J Am Med Dir Assoc. 2013;14(12):895–900.Google Scholar
  10. 10.
    Janus SI, van Manen JG, Zuidema SU, Snijder C, Drossaert CH, Ijzerman MJ. Reasons for (not) discontinuing antipsychotics in dementia. Psychogeriatrics. 2018;18(1):13–20.Google Scholar
  11. 11.
    Pulsford D, Duxbury J. Aggressive behaviour by people with dementia in residential care settings: a review. J Psychiatr Ment Health Nurs. 2006;13(5):611–8.Google Scholar
  12. 12.
    Cubit K, Farrell G, Robinson A, Myhill M. A survey of the frequency and impact of behaviours of concern in dementia on residential aged care staff. Australas J Ageing. 2007;26(2):64–70.Google Scholar
  13. 13.
    Hoe J, Hancock G, Livingston G, Orrell M. Quality of life of people with dementia in residential care homes. Br J Psychiatry. 2018;188(5):460–4.Google Scholar
  14. 14.
    Zhao Q-F, Tan L, Wang H-F, Jiang T, Tan M-S, Tan L, et al. The prevalence of neuropsychiatric symptoms in Alzheimer’s disease: systematic review and meta-analysis. J Affect Disord. 2016;190:264–71.Google Scholar
  15. 15.
    Seitz DP, Adunuri N, Gill SS, Gruneir A, Herrmann N, Rochon P. Antidepressants for agitation and psychosis in dementia. Cochrane Database Syst Rev. 2011;16(2):Cd008191.Google Scholar
  16. 16.
    Porsteinsson AP, Drye LT, Pollock BG, Devanand DP, Frangakis C, Ismail Z, et al. Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial. J Am Med Assoc. 2014;311(7):682–91.Google Scholar
  17. 17.
    Buterbaugh WM, Jamrose T, Lazzara J, Honaker L, Thomas CJ. Review of antidepressants in the treatment of behavioral and psychiatric symptoms in dementia (BPSD). Ment Health Clin. 2014;4(4):183–8.Google Scholar
  18. 18.
    Rosenberg PB, Martin BK, Frangakis C, Mintzer JE, Weintraub D, Porsteinsson AP, et al. Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry. 2010;18(2):136–45.Google Scholar
  19. 19.
    Banerjee S, Hellier J, Dewey M, Romeo R, Ballard C, Baldwin R, et al. Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet. 2011;378(9789):403–11.Google Scholar
  20. 20.
    Banerjee S. The use of antipsychotic medication for people with dementia: time for action. A report for the Minister of State for Care Services United Kingdom Department of Health From the website. 2009.Google Scholar
  21. 21.
    Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer’s disease: a pooled analysis of 3 studies. J Clin Psychiatry. 2008;69(3):341–8.Google Scholar
  22. 22.
    Kales HC, Lyketsos CG, Miller EM, Ballard C. Management of behavioral and psychological symptoms in people with Alzheimer’s disease: an international Delphi consensus. Int Psychogeriatr. 2018;2:1–8.Google Scholar
  23. 23.
    Tible OP, Riese F, Savaskan E, von Gunten A. Best practice in the management of behavioural and psychological symptoms of dementia. Ther Adv Neurol Disord. 2017;10(8):297–309.Google Scholar
  24. 24.
    Ralph SJ, Espinet AJ. Increased all-cause mortality by antipsychotic drugs: updated review and meta-analysis in dementia and general mental health care. J Alzheimer’s Dis Rep. 2018;2(1):287–312.Google Scholar
  25. 25.
    Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. J Am Med Assoc. 2005;294(15):1934–43.Google Scholar
  26. 26.
    Tampi RR, Tampi DJ, Balachandran S, Srinivasan S. Antipsychotic use in dementia: a systematic review of benefits and risks from meta-analyses. Ther Adv Chronic Dis. 2016;7(5):229–45.Google Scholar
  27. 27.
    Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, et al. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2013;4:CD007726.Google Scholar
  28. 28.
    Defrancesco M, Marksteiner J, Fleischhacker WW, Blasko I. Use of benzodiazepines in Alzheimer’s disease: a systematic review of literature. Int J Neuropsychopharmacol. 2015;18(10):pvy055.Google Scholar
  29. 29.
    Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioural and psychological symptoms of dementia: a literature review. Int Psychogeriatr. 2008;20(2):293–308.Google Scholar
  30. 30.
    Gustafsson M, Isaksson U, Karlsson S, Sandman P-O, Lövheim H. Behavioral and psychological symptoms and psychotropic drugs among people with cognitive impairment in nursing homes in 2007 and 2013. Eur J Clin Pharmacol. 2016;72(8):987–94.Google Scholar
  31. 31.
    Jacquin-Piques A, Sacco G, Tavassoli N, Rouaud O, Bejot Y, Giroud M, et al. Psychotropic drug prescription in patients with dementia: nursing home residents versus patients living at home. J Alzheimer’s Dis. 2016;49(3):671–80.Google Scholar
  32. 32.
    Janus SI, van Manen JG, IJzerman MJ, Zuidema SU. Psychotropic drug prescriptions in Western European nursing homes. Int Psychogeriatr. 2016;28(11):1775–90.Google Scholar
  33. 33.
    Chen Y, Briesacher BA, Field TS, Tjia J, Lau DT, Gurwitz JH. Unexplained variation across us nursing homes in antipsychotic prescribing rates. Arch Intern Med. 2010;170(1):89–95.Google Scholar
  34. 34.
    Shah SM, Carey IM, Harris T, DeWilde S, Cook DG. Quality of prescribing in care homes and the community in England and Wales. Br J Gen Pract. 2012;62(598):e329–36.Google Scholar
  35. 35.
    Stevenson DG, Decker SL, Dwyer LL, Huskamp HA, Grabowski DC, Metzger ED, et al. Antipsychotic and benzodiazepine use among nursing home residents: findings from the 2004 National Nursing Home Survey. Am J Geriatr Psychiatry. 2010;18(12):1078–92.Google Scholar
  36. 36.
    Nørgaard A, Jensen-Dahm C, Gasse C, Hansen ES, Waldemar G. Psychotropic polypharmacy in patients with dementia: prevalence and predictors. J Alzheimer’s Dis. 2017;56(2):707–16.Google Scholar
  37. 37.
    Rojas-Fernandez C, Mikhail M, Brown SG. Psychotropic and cognitive-enhancing medication use and its documentation in contemporary long-term care practice. Ann Pharmacother. 2014;48(4):438–46.Google Scholar
  38. 38.
    van der Spek K, Gerritsen DL, Smalbrugge M, Nelissen-Vrancken MH, Wetzels RB, Smeets CH, et al. Only 10% of the psychotropic drug use for neuropsychiatric symptoms in patients with dementia is fully appropriate. The PROPER I-study. Int Psychogeriatr. 2016;28(10):1589–95.Google Scholar
  39. 39.
    de Oliveira AM, Radanovic M, de Mello PC, Buchain PC, Vizzotto AD, Celestino DL, et al. Nonpharmacological interventions to reduce behavioral and psychological symptoms of dementia: a systematic review. BioMed Res Int. 2015;2015:218980.Google Scholar
  40. 40.
    Livingston G, Kelly L, Lewis-Holmes E, Baio G, Morris S, Patel N, et al. Non-pharmacological interventions for agitation in dementia: systematic review of randomised controlled trials. Br J Psychiatry. 2014;205(6):436–42.Google Scholar
  41. 41.
    Edvardsson D, Sandman PO, Borell L. Implementing national guidelines for person-centered care of people with dementia in residential aged care: effects on perceived person-centeredness, staff strain, and stress of conscience. Int Psychogeriatr. 2014;26(7):1171–9.Google Scholar
  42. 42.
    Daly RL, Bunn F, Goodman C. Shared decision-making for people living with dementia in extended care settings: a systematic review. BMJ Open. 2018;8(6):e018977.Google Scholar
  43. 43.
    Chenoweth L, Forbes I, Fleming R, King MT, Stein-Parbury J, Luscombe G, et al. PerCEN: a cluster randomized controlled trial of person-centered residential care and environment for people with dementia. Int Psychogeriatr. 2014;26(7):1147–60.Google Scholar
  44. 44.
    Moniz Cook ED, Swift K, James I, Malouf R, De Vugt M, Verhey F. Functional analysis-based interventions for challenging behaviour in dementia. Cochrane Database Syst Rev. 2012;15(2):Cd006929.Google Scholar
  45. 45.
    Fraker J, Kales HC, Blazek M, Kavanagh J, Gitlin LN. The role of the occupational therapist in the management of neuropsychiatric symptoms of dementia in clinical settings. Occup Ther Health Care. 2014;28(1):4–20.Google Scholar
  46. 46.
    Kales HC, Gitlin LN, Lyketsos CG. Assessment and management of behavioral and psychological symptoms of dementia. BMJ. 2015;350:h369.Google Scholar
  47. 47.
    van der Steen J, Smaling H, Bruinsma M, Scholten R, Vink A. Music-based therapeutic interventions for people with dementia. Cochrane Database Syst Rev. 2018;7:CD003477.Google Scholar
  48. 48.
    Gerdner LA. Effects of individualized versus classical “relaxation” music on the frequency of agitation in elderly persons with Alzheimer’s disease and related disorders. Int Psychogeriatr. 2000;12(1):49–65.Google Scholar
  49. 49.
    Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–734.Google Scholar
  50. 50.
    Tsoi KKF, Chan JYC, Ng YM, Lee MMY, Kwok TCY, Wong SYS. Receptive music therapy is more effective than interactive music therapy to relieve behavioral and psychological symptoms of dementia: a systematic review and meta-analysis. J Am Med Dir Assoc. 2018;19(7):568–76.Google Scholar
  51. 51.
    Orgeta V, Qazi A, Spector A, Orrell M. Psychological treatments for depression and anxiety in dementia and mild cognitive impairment: systematic review and meta-analysis. Br J Psychiatry. 2015;207(4):293–8.Google Scholar
  52. 52.
    Woods B, O’Philbin L, Farrell EM, Spector AE, Orrell M. Reminiscence therapy for dementia. Cochrane Database Syst Rev. 2018;3:Cd001120.Google Scholar
  53. 53.
    Forrester LT, Maayan N, Orrell M, Spector AE, Buchan LD, Soares-Weiser K. Aromatherapy for dementia. Cochrane Database Syst Rev. 2014;25(2):Cd003150.Google Scholar
  54. 54.
    Lamb SE, Sheehan B, Atherton N, Nichols V, Collins H, Mistry D, et al. Dementia and physical activity (DAPA) trial of moderate to high intensity exercise training for people with dementia: randomised controlled trial. BMJ. 2018;361:k1675.Google Scholar
  55. 55.
    Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S. Exercise programs for people with dementia. Cochrane Database Syst Rev. 2015;15(4):Cd006489.Google Scholar
  56. 56.
    Yakimicki ML, Edwards NE, Richards E, Beck AM. Animal-assisted intervention and dementia: a systematic review. Clin Nurs Res. 2018.  https://doi.org/10.1177/1054773818756987.Google Scholar
  57. 57.
    Chenoweth L, King MT, Jeon YH, Brodaty H, Stein-Parbury J, Norman R, et al. Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurol. 2009;8(4):317–25.Google Scholar
  58. 58.
    Low L-F, Brodaty H, Goodenough B, Spitzer P, Bell J-P, Fleming R, et al. The Sydney Multisite Intervention of LaughterBosses and ElderClowns (SMILE) study: cluster randomised trial of humour therapy in nursing homes. BMJ Open. 2013;3:e002072.Google Scholar
  59. 59.
    Brodaty H, Low L-F, Liu Z, Fletcher J, Roast J, Goodenough B, et al. Successful ingredients in the SMILE study: resident, staff, and management factors influence the effects of humor therapy in residential aged care. Am J Geriatr Psychiatry. 2014;22(12):1427–37.Google Scholar
  60. 60.
    Verbeek H, Zwakhalen SM, van Rossum E, Ambergen T, Kempen GI, Hamers JP. Effects of small-scale, home-like facilities in dementia care on residents’ behavior, and use of physical restraints and psychotropic drugs: a quasi-experimental study. Int Psychogeriatr. 2014;26(4):657–68.Google Scholar
  61. 61.
    Harrison SL, Bradley C, Milte R, Liu E, Kouladjian O’Donnell L, Hilmer SN, et al. Psychotropic medications in older people in residential care facilities and associations with quality of life: a cross-sectional study. BMC Geriatr. 2018;18(1):60.Google Scholar
  62. 62.
    Health Care Financing Administration. Survey procedures and interpretive guidelines for skilled nursing facilities and intermediate care facilities. Baltimore; 1990.Google Scholar
  63. 63.
    Stoudemire A, Smith DA. OBRA regulations and the use of psychotropic drugs in long-term care facilities: impact and implications for geropsychiatric care. Gen Hosp Psychiatry. 1996;18(2):77–94.Google Scholar
  64. 64.
    Llorente MD, Olsen EJ, Leyva O, Silverman MA, Lewis JE, Rivero J. Use of antipsychotic drugs in nursing homes: current compliance with OBRA regulations. J Am Geriatr Soc. 1998;46(2):198–201.Google Scholar
  65. 65.
    Hughes CM, Lapane KL, Mor V, Ikegami N, Jonsson PV, Ljunggren G, et al. The impact of legislation on psychotropic drug use in nursing homes: a cross-national perspective. J Am Geriatr Soc. 2000;48(8):931–7.Google Scholar
  66. 66.
    Huybrechts KF, Rothman KJ, Brookhart MA, Silliman RA, Crystal S, Gerhard T, et al. Variation in antipsychotic treatment choice across US nursing homes. J Clin Psychopharmacol. 2012;32(1):11–7.Google Scholar
  67. 67.
    Therapeutic Goods Administration. Risperidone and risk of cerebrovascular adverse events in dementia patients. Med Saf Update. 2015. https://www.tga.gov.au/publication-issue/medicines-safety-update-volume-6-number-4-august-2015#risperidone. Accessed 10 Aug 2018.
  68. 68.
    Dorsey ER, Rabbani A, Gallagher SA, Conti RM, Alexander GC. Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med. 2010;170(1):96–103.Google Scholar
  69. 69.
    Singh RR, Nayak R. Impact of FDA black box warning on psychotropic drug use in noninstitutionalized elderly patients diagnosed with dementia: a retrospective study. J Pharm Pract. 2016;29(5):495–502.Google Scholar
  70. 70.
    Szczepura A, Wild D, Khan AJ, Owen DW, Palmer T, Muhammad T, et al. Antipsychotic prescribing in care homes before and after launch of a national dementia strategy: an observational study in English institutions over a 4-year period. BMJ Open. 2016;6(9):e009882.Google Scholar
  71. 71.
    Alldred DP, Kennedy MC, Hughes C, Chen TF, Miller P. Interventions to optimise prescribing for older people in care homes. Cochrane Database Syst Rev. 2016;2:Cd009095.Google Scholar
  72. 72.
    National Institute for Health and Care Excellend. Medication management in nursing homes. Quality statement 5: medication reviews. 2015. https://www.nice.org.uk/guidance/qs85/chapter/quality-statement-5-medication-reviews. Accessed 28 Nov 2018.
  73. 73.
    Register Federal. Medicare and Medicaid programs; reform of requirements for long-term care facilities. Final rule. Fed Regist. 2016;81(192):68688–872.Google Scholar
  74. 74.
    Pharmaceutical Society of Australia. Guidelines for pharmacists providing Residential Medication Management Review (RMMR) and Quality Use of Medicines (QUM) services. 2011. www.psa.org.au/site.php?id=6730. Accessed 20 May 2018.
  75. 75.
    Kallio SE, Kiiski A, Airaksinen MSA, Mantyla AT, Kumpusalo-Vauhkonen AEJ, Jarvensivu TP, et al. Community pharmacists’ contribution to medication reviews for older adults: a systematic review. J Am Geriatr Soc. 2018;66(8):1613–20.Google Scholar
  76. 76.
    NHS England. Medicines optimisation in care homes. https://www.england.nhs.uk/commissioning/primary-care/pharmacy/medicines-optimisation-in-care-homes/. Accessed 10 Aug 2018.
  77. 77.
    Nishtala PS, Hilmer SN, McLachlan AJ, Hannan PJ, Chen TF. Impact of residential medication management reviews on drug burden index in aged-care homes: a retrospective analysis. Drugs Aging. 2009;26(8):677–86.Google Scholar
  78. 78.
    Thiruchelvam K, Hasan SS, Wong PS, Kairuz T. Residential aged care medication review to improve the quality of medication use: a systematic review. J Am Med Dir Assoc. 2017;18(1):87.e1–.e14.Google Scholar
  79. 79.
  80. 80.
    Sawan MJ, Jeon YH, Fois RJ, Chen TF. A qualitative study exploring visible components of organizational culture: what influences the use of psychotropic medicines in nursing homes? Int Psychogeriatr. 2016;28(10):1725–35.Google Scholar
  81. 81.
    Rendina N, Brodaty H, Draper B, Peisah C, Brugue E. Substitute consent for nursing home residents prescribed psychotropic medication. Int J Geriatr Psychiatry. 2009;24(3):226–31.Google Scholar
  82. 82.
    Plakiotis C, Bell JS, Jeon YH, Pond D, O’Connor DW. Deprescribing psychotropic medications in aged care facilities: the potential role of family members. Adv Exp Med Biol. 2015;821:29–43.Google Scholar
  83. 83.
    Devanand DP, Mintzer J, Schultz SK, Andrews HF, Sultzer DL, de la Pena D, et al. Relapse risk after discontinuation of risperidone in Alzheimer’s disease. N Engl J Med. 2012;367(16):1497–507.Google Scholar
  84. 84.
    Brodaty H, Aerts L, Harrison F, Jessop T, Cations M, Chenoweth L, et al. Antipsychotic deprescription for older adults in long-term care: the HALT study. J Am Med Dir Assoc. 2018;19(7):592–600.e7.Google Scholar
  85. 85.
    Chenoweth L, Jessop T, Harrison F, Cations M, Cook J, Brodaty H. Critical contextual elements in facilitating and achieving success with a person-centred care intervention to support antipsychotic deprescribing for older people in long-term care. BioMed Res Int. 2018;2018:12.Google Scholar
  86. 86.
    Westbury JL, Gee P, Ling T, Brown DT, Franks KH, Bindoff I, et al. RedUSe: reducing antipsychotic and benzodiazepine prescribing in residential aged care facilities. Med J Aust. 2018;208(9):398–403.Google Scholar
  87. 87.
    Fossey J, Ballard C, Juszczak E, James I, Alder N, Jacoby R, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ. 2006;332(7544):756–61.Google Scholar
  88. 88.
    Lawrence V, Fossey J, Ballard C, Moniz-Cook E, Murray J. Improving quality of life for people with dementia in care homes: making psychosocial interventions work. Br J Psychiatry. 2012;201(5):344–51.Google Scholar
  89. 89.
    van der Spek K, Koopmans R, Smalbrugge M, Nelissen-Vrancken M, Wetzels RB, Smeets CHW, et al. The effect of biannual medication reviews on the appropriateness of psychotropic drug use for neuropsychiatric symptoms in patients with dementia: a randomised controlled trial. Age Ageing. 2018;47(3):430–7.Google Scholar
  90. 90.
    Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol. 2009;8(2):151–7.Google Scholar
  91. 91.
    The Royal Australian & New Zealand College of Psychiatrists. Antipsychotic medications as a treatment of behavioural and psychological symptoms of dementia. 2016. https://www.ranzcp.org/Files/Resources/College_Statements/Practice_Guidelines/pg10-pdf.aspx. Accessed 20 Jul 2018.
  92. 92.
    Reeve E, Ong M, Wu A, Jansen J, Petrovic M, Gnjidic D. A systematic review of interventions to deprescribe benzodiazepines and other hypnotics among older people. Eur J Clin Pharmacol. 2017;73(8):927–35.Google Scholar
  93. 93.
    Paquin AM, Zimmerman K, Rudolph JL. Risk versus risk: a review of benzodiazepine reduction in older adults. Expert Opin Drug Saf. 2014;13(7):919–34.Google Scholar
  94. 94.
    Gosselin P, Ladouceur R, Morin CM, Dugas MJ, Baillargeon L. Benzodiazepine discontinuation among adults with GAD: a randomized trial of cognitive-behavioral therapy. J Consult Clin Psychol. 2006;74(5):908–19.Google Scholar
  95. 95.
    Morin CM, Bastien C, Guay B, Radouco-Thomas M, Leblanc J, Vallieres A. Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia. Am J Psychiatry. 2004;161(2):332–42.Google Scholar
  96. 96.
    Vicens C, Fiol F, Llobera J, Campoamor F, Mateu C, Alegret S, et al. Withdrawal from long-term benzodiazepine use: randomised trial in family practice. Br J Gen Pract. 2006;56(533):958–63.Google Scholar
  97. 97.
    Orgeta V, Tabet N, Nilforooshan R, Howard R. Efficacy of antidepressants for depression in Alzheimer’s disease: systematic review and meta-analysis. J Alzheimer’s Dis. 2017;58(3):725–33.Google Scholar
  98. 98.
    Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. Psychother Psychosom. 2015;84(2):72–81.Google Scholar
  99. 99.
    Bergh S, Selbaek G, Engedal K. Discontinuation of antidepressants in people with dementia and neuropsychiatric symptoms (DESEP study): double blind, randomised, parallel group, placebo controlled trial. BMJ. 2012;344:e1566.Google Scholar
  100. 100.
    Reeve E, Bell JS, Hilmer SN. Barriers to optimising prescribing and deprescribing in older adults with dementia: a narrative review. Curr Clin Pharmacol. 2015;10(3):168–77.Google Scholar
  101. 101.
    Anderson K, Stowasser D, Freeman C, Scott I. Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open. 2014;4(12):e006544.Google Scholar
  102. 102.
    Turner JP, Edwards S, Stanners M, Shakib S, Bell JS. What factors are important for deprescribing in Australian long-term care facilities? Perspectives of residents and health professionals. BMJ Open. 2016;6(3):e009781.Google Scholar
  103. 103.
    Zhang Y, Letuchy EM, Carnahan RM. Where are antipsychotics prescribed in nursing homes initiated? J Am Geriatr Soc. 2018;66(6):1082–8.Google Scholar
  104. 104.
    Sawan M, Chen T, Jeon YH, Hilmer SN. Interventions to reduce antipsychotic prescribing in nursing homes must cross healthcare silos. J Am Geriatr Soc. 2018;66(6):1235–6.Google Scholar
  105. 105.
    Barry MJ, Edgman-Levitan S. Shared decision making—pinnacle of patient-centered care. N Engl J Med. 2012;366(9):780–1.Google Scholar
  106. 106.
    Kalogianis MJ, Wimmer BC, Turner JP, Tan EC, Emery T, Robson L, et al. Are residents of aged care facilities willing to have their medications deprescribed? Res Soc Admin Pharm. 2016;12(5):784–8.Google Scholar
  107. 107.
    Jansen J, Naganathan V, Carter SM, McLachlan AJ, Nickel B, Irwig L, et al. Too much medicine in older people? Deprescribing through shared decision making. BMJ. 2016;353:i2893.Google Scholar
  108. 108.
    Sawan M, Jeon YH, Chen TF. Shaping the use of psychotropic medicines in nursing homes: a qualitative study on organisational culture. Soc Sci Med. 2018;202:70–8.Google Scholar
  109. 109.
    Sawan M, Jeon YH, Fois RA, Chen TF. Exploring the link between organizational climate and the use of psychotropic medicines in nursing homes: a qualitative study. Res Soc Admin Pharm. 2017;13(3):513–23.Google Scholar
  110. 110.
    Jennings AA, Foley T, Walsh KA, Coffey A, Browne JP, Bradley CP. General practitioners’ knowledge, attitudes, and experiences of managing behavioural and psychological symptoms of dementia: a mixed-methods systematic review. Int J Geriatr Psychiatry. 2018;7(1):62.Google Scholar
  111. 111.
    Ailabouni NJ, Nishtala PS, Mangin D, Tordoff JM. Challenges and enablers of deprescribing: a general practitioner perspective. PLoS One. 2016;11(4):e0151066.Google Scholar
  112. 112.
    Tjia J, Gurwitz JH, Briesacher BA. Challenge of changing nursing home prescribing culture. Am J Geriatr Pharmacother. 2012;10(1):37–46.Google Scholar
  113. 113.
    Reeve E, Anthony AC, Kouladjian O’Donnell L, Low LF, Ogle SJ, Glendenning JE, et al. Development and pilot testing of the revised Patients’ Attitudes Towards Deprescribing questionnaire for people with cognitive impairment. Australas J Ageing. 2018.  https://doi.org/10.1111/ajag.12576.Google Scholar
  114. 114.
    Reeve E, Low LF, Shakib S, Hilmer SN. Development and validation of the Revised Patients’ Attitudes Towards Deprescribing (rPATD) Questionnaire: versions for older adults and caregivers. Drugs Aging. 2016;33(12):913–28.Google Scholar
  115. 115.
    Olivieri-Mui BL, Devlin JW, Ochoa A, Schenck D, Briesacher B. Perceptions vs. evidence: therapeutic substitutes for antipsychotics in patients with dementia in long-term care. Aging Ment Health. 2018;22(4):544–9.Google Scholar
  116. 116.
    Anrys P, Strauven G, Boland B, Dalleur O, Declercq A, Degryse J-M, et al. Collaborative approach to Optimise MEdication use for Older people in Nursing homes (COME-ON): study protocol of a cluster controlled trial. Implement Sci. 2015;11(1):35.Google Scholar
  117. 117.
    Mahlknecht A, Nestler N, Bauer U, Schüßler N, Schuler J, Scharer S, et al. Effect of training and structured medication review on medication appropriateness in nursing home residents and on cooperation between health care professionals: the InTherAKT study protocol. BMC Geriatr. 2017;17(1):24.Google Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.Registry of Older South AustraliansSouth Australian Health and Medical Research Institute (SAHMRI)AdelaideAustralia
  2. 2.NHMRC Cognitive Decline Partnership CentreThe University of SydneySydneyAustralia
  3. 3.Department of Rehabilitation, Aged and Extended Care, College of Medicine and Public HealthFlinders University, Flinders Medical Centre, Bedford ParkAdelaideAustralia
  4. 4.Dementia Centre for Research Collaboration, School of PsychiatryUNSW SydneySydneyAustralia
  5. 5.Department of Clinical Pharmacology and Aged CareRoyal North Shore Hospital and Kolling InstituteSt LeonardsAustralia
  6. 6.Academic Department for Old Age PsychiatryPrince of Wales HospitalRandwickAustralia
  7. 7.Centre for Healthy Brain Ageing, UNSW SydneySydneyAustralia

Personalised recommendations